Abstract The present invention relates to an amorphous form of Panobinostat Lactate hydrate. In particular, the present invention relates to processes for the preparation of amorphous form of Panobinostat Lactate. More particular the present invention relates to the pharmaceutical composition comprising an amorphous Panobinostat Lactate and one or more of pharmaceutically acceptable carriers, excipients or diluents used for the treatment of Multiple myeloma. The present invention relates to an amorphous form of Panobinostat and its process for the preparation thereof.
